TIGD7

Across TCGA pan-cancer cohorts, TIGD7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TIGD7 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TIGD7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TIGD7 expression acts as an unfavorable survival marker.

LSCC and LUAD are the cancer types where TIGD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.227	1.000	.038	4	view →
LUAD	DFS	Median	All	0.731	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TIGD7–LSCC (DFS)

Open the LSCC breakdown →